licens
live
attenu
viru
vaccin
capabl
express
transgen
pathogen
potenti
reduc
number
childhood
immun
elicit
robust
immun
multipl
pathogen
simultan
recombin
attenu
measl
viru
rmv
deriv
edmonston
zagreb
vaccin
strain
engin
express
simian
immunodefici
viru
siv
gag
protein
purpos
evalu
immunogen
rmv
vaccin
vector
rhesu
macaqu
rmvgag
immun
alon
elicit
robust
measlesspecif
humor
cellular
respons
fail
elicit
transgen
gag
specif
immun
respons
follow
aerosol
intratrachealintramuscular
deliveri
howev
administ
prime
vaccin
heterolog
boost
recombin
adenoviru
serotyp
express
transgen
rmvgag
significantli
enhanc
gagspecif
lymphocyt
respons
follow
immun
gagspecif
humor
respons
enhanc
howev
may
due
either
transgen
vector
cellular
respons
prime
rmv
transgen
highli
effect
even
use
suboptim
dose
boost
data
demonstr
feasibl
use
rmv
prime
compon
heterolog
primeboost
vaccin
regimen
pathogen
requir
strong
cellular
respons
vaccin
measl
implement
expand
program
immun
sinc
million
children
safe
immun
protect
diseas
current
regist
vaccin
base
live
attenu
measl
virus
gener
extens
propag
attenu
cell
cultur
although
differ
measl
vaccin
differ
way
attenu
share
durabl
efficaci
safeti
record
protect
immun
measl
effici
induc
measl
vaccin
immun
strongli
stimul
innat
adapt
immun
respons
measlesspecif
humor
respons
detect
long
year
vaccin
possibl
due
boost
natur
exposur
measl
vaccin
excel
safeti
record
inject
also
mucos
aerosol
deliveri
mucos
deliveri
mimic
natur
infect
known
highli
immunogen
number
vaccin
campaign
demonstr
superior
immunogen
aerosol
deliv
edmonston
zagreb
ez
measl
vaccin
compar
inject
vaccin
either
primari
boost
immun
safeti
attenu
measl
vaccin
proven
numer
clinic
trial
postmarket
surveil
good
safeti
profil
attenu
measl
vaccin
due
high
stabil
viral
genom
prevent
revers
highli
virul
speci
addit
measl
viru
nonseg
singl
strand
neg
rna
viru
replic
exclus
cytoplasm
infect
cell
thu
viral
genom
integr
host
chromosom
due
straightforward
manufactur
measl
vaccin
produc
larg
scale
low
cost
safeti
record
immunogen
manufactur
make
live
attenu
measl
viru
attract
candid
develop
recombin
vaccin
vector
recombin
measl
vaccin
rmv
vector
antigen
anoth
pathogen
incorpor
measl
genom
replic
transcript
rmv
cell
transgen
express
togeth
viral
protein
present
host
immun
system
induc
transgenespecif
immun
respons
thu
multival
vaccin
vector
would
induc
strong
immun
protect
measl
also
anoth
pathogen
number
differ
transgen
includ
gene
human
papilloma
viru
sar
coronaviru
west
nile
viru
human
simian
immunodefici
virus
hivsiv
stabli
incorpor
recombin
measl
genom
demonstr
transgen
protein
express
vivo
studi
measl
viru
recombin
measl
vector
tradit
perform
immunocompromis
receptor
mice
transgen
human
receptor
measl
viru
receptor
immunogen
studi
anim
demonstr
recombin
measl
vector
induc
strong
immun
respons
measl
also
transgen
immunocompet
mice
howev
immun
respons
transgen
gener
low
even
though
measlesspecif
respons
well
induc
unpublish
data
possibl
reflect
inabl
measl
vector
effici
replic
anim
initi
immunogen
studi
perform
nonhuman
primat
use
rmv
vector
base
licens
ez
vaccin
strain
backbon
express
sivgag
rmvgag
fail
demonstr
transgen
specif
respons
anim
develop
measl
specif
immun
respons
data
shown
assum
due
highli
attenu
natur
ez
strain
one
safest
measl
vaccin
current
use
would
argu
use
recombin
measl
vector
standalon
vaccin
pathogen
current
studi
evalu
whether
recombin
measl
vector
could
enhanc
immun
respons
combin
heterolog
vaccin
vector
heterolog
primeboost
immun
regimen
highli
promis
vaccin
approach
current
evalu
differ
diseas
includ
proven
difficult
pathogen
malaria
parasit
mycobacterium
tuberculosi
hiv
heterolog
primeboost
regimen
may
improv
magnitud
also
qualiti
immun
respons
increas
epitop
coverag
function
respons
due
differ
mechan
uptak
process
differ
vaccin
vector
vivo
experiment
intratrach
aerosol
ae
deliveri
use
success
sever
anim
experi
advantag
inocul
ensur
deliveri
complet
viral
dose
lung
howev
attenu
measl
edmonston
tag
strain
inocul
replic
upper
respiratori
tract
follow
ae
inhal
sinc
ez
vaccin
strain
may
behav
differ
pursu
mucos
deliveri
rout
increas
possibl
viral
replic
upper
lower
respiratori
tract
effici
elicit
mucos
immun
respons
viral
vector
insert
transgen
report
humor
cellular
immunogen
recombin
live
attenu
measl
viru
rmv
express
sivgag
use
primarili
mucos
vaccin
vector
rhesu
macaqu
rmv
fail
elicit
robust
immun
respons
recombin
insert
despit
induc
robust
respons
measl
viru
howev
administ
prime
immun
recombin
adenoviru
serotyp
express
immunogen
rmv
significantli
enhanc
sivgag
specif
tcell
respons
particular
cell
true
even
otherwis
inert
suboptim
dose
use
boost
vaccin
find
reveal
potenti
role
rmv
prime
compon
heterolog
primeboost
vaccin
regimen
pathogen
simultan
immun
measl
creat
rmv
vector
express
foreign
protein
cdna
correspond
antigenom
edmonston
zagreb
vaccin
strain
clone
addit
transcript
unit
insert
exogen
gene
encod
foreign
antigen
viral
genom
studi
two
measl
vector
use
rmv
empti
rmveznul
rmvnull
rmv
contain
gag
gene
posit
p
gene
rmvgag
virus
rescu
previous
describ
vaccin
batch
prepar
cell
describ
modif
brief
recombin
measl
vector
grown
cell
roller
bottl
co
virus
harvest
sever
time
point
post
infect
viral
titer
determin
standard
plaqu
assay
vero
cell
presenc
transgen
confirm
rtpcr
sequenc
protein
express
confirm
western
blot
antisiv
gag
antibodi
nih
aid
research
refer
reagent
program
recombin
construct
express
gagpol
siv
viru
stock
gener
previous
describ
colonybr
indianorigin
rhesu
macaqu
immun
describ
result
section
briefli
rmv
administ
either
singl
human
dose
pfu
pfu
either
studi
studi
b
studi
five
anim
seroposit
studi
start
assign
one
per
rmvgag
prime
group
three
prime
group
aerosol
immun
deliv
ml
nebul
system
pari
pharma
germani
studi
b
standard
im
immun
conduct
use
ml
vaccin
rmvnull
group
rmvgag
group
measl
studi
anim
hous
bioqual
inc
rockvil
md
studi
b
new
england
primat
research
center
harvard
medic
school
southborough
anim
maintain
accord
nation
institut
health
harvard
medic
school
guidelin
neutral
antibodi
adenoviru
serotyp
detect
luciferas
transgen
express
inhibit
made
previous
describ
briefli
heat
inactiv
serum
sampl
twofold
serial
dilut
medium
dulbecco
modifi
eagl
medium
contain
fb
duplic
serum
dilut
rang
end
volum
medium
plate
fix
amount
adenoviru
adapt
luc
puml
ad
serum
dilut
incub
min
room
temperatur
cell
ad
everi
well
plate
incub
hr
co
medium
discard
phosphatebuff
salin
pb
ad
one
freezethaw
cycl
made
next
steadylit
luciferas
assay
system
reagent
perkin
elmer
ad
everi
well
incub
min
room
temperatur
well
transfer
black
white
isopl
luminesc
count
measur
microbeta
trilux
neg
control
serum
ad
result
maximum
luciferas
activ
minimum
luciferas
activ
obtain
well
viru
ad
posit
control
serum
immun
mice
use
neutral
titer
calcul
nonlinear
curv
fit
sampl
data
use
minimum
luciferas
activ
control
viru
baselin
maximum
luciferas
activ
control
serum
plateau
enzym
immunoassay
use
measur
mvspecif
igg
studi
previous
describ
modif
briefli
sera
dilut
incub
overnight
mvinfect
vero
cell
lysat
advanc
biotechnolog
coat
maxisorp
plate
nalg
nunc
intern
plate
wash
time
pb
contain
pbst
alkalin
phosphataseconjug
rabbit
antimonkey
igg
biomakor
accur
chemic
ad
well
plate
incub
hour
follow
four
wash
pbst
plate
develop
use
substrat
paranitrophenyl
phosphat
sigmafast
sigma
absorb
read
softmax
pro
softwar
molecular
devic
averag
three
sampl
report
optic
densiti
three
neg
control
use
plasma
monkey
includ
assay
neg
averag
optic
densiti
studi
b
antimv
igg
antibodi
measur
use
fisherbrand
high
proteinbind
microtit
plate
coat
hr
room
temperatur
ngwell
betapropiolactoneinactiv
measl
viru
edmonston
strain
atcc
virionserion
wurzburg
germani
carbon
buffer
ph
plate
wash
pbst
block
min
goat
serum
gs
pbst
pool
serum
mvimmun
macaqu
arbitrarili
assign
unitsml
antimv
igg
antibodi
use
standard
individu
serum
sampl
test
eight
serial
dilut
use
start
dilut
overnight
reaction
plate
wash
pbst
treat
ngwell
biotinyl
goat
antihuman
igg
southernbiotech
birmingham
al
plate
wash
react
min
room
temperatur
ngwell
streptavidinperoxidas
sigma
final
develop
tetramethylbenzidin
southernbiotech
min
sulfur
acid
stop
solut
absorb
record
nm
spectramax
plate
reader
molecular
devic
sunnyval
ca
serum
consid
posit
igg
antibodi
postimmun
level
greater
preimmun
level
plaqu
reduct
neutral
assay
use
measur
neutral
antibodi
titer
follow
immun
dilut
monkey
serum
sampl
twofold
serial
dilut
standard
rd
intern
antimeasl
standard
serum
iuml
nibsc
code
nibsc
potter
bar
hertfodshir
uk
serial
dilut
serum
dilut
incub
fix
amount
approxim
pfuml
hr
vero
cell
seed
plate
infect
serummv
mix
humid
chamber
hr
overlaid
semisolid
medium
mem
methocel
incub
day
co
cell
fix
stain
formaldehyd
gl
crystal
violet
pb
ph
plaqu
count
neutral
endpoint
titer
calcul
use
spearman
method
neutral
defin
plaqu
geometr
mean
plaqu
count
serum
neg
control
normal
titer
calcul
ratio
estim
neutral
endpoint
standard
multipli
titer
iuml
log
sampl
log
iuml
neutral
endpoint
valu
less
ie
first
dilut
consid
neg
titer
miuml
consid
preimmun
postimmun
serum
bal
rectal
spong
eluat
analyz
humor
respons
elisa
previous
describ
rectal
secret
sampl
modifi
wick
method
use
weckcel
spear
windsor
biomed
newton
nh
previous
describ
sivspecif
iga
igg
antibodi
gag
measur
use
microtit
plate
coat
respect
siv
viral
lysat
ng
total
proteinwel
advanc
biotechnolog
inc
columbia
md
total
iga
igg
measur
use
plate
coat
goat
antimonkey
iga
rockland
gilbertsvil
pa
igg
mp
biomed
solon
oh
pool
macaqu
serum
contain
previous
calibr
amount
relev
antibodi
immunoglobulin
use
standard
plate
develop
biotinyl
goat
antimonkey
iga
ngml
openbiosystem
huntsvil
al
antihuman
igg
describ
secret
concentr
antigenspecif
iga
divid
concentr
total
iga
sampl
obtain
specif
activ
result
consid
contain
signific
antibodi
specif
activ
mean
standard
deviat
neg
control
preimmun
specif
activ
peripher
blood
bal
collect
anim
follow
immun
singl
cell
suspens
stimul
overlap
peptid
pool
mv
nprotein
siv
gag
hour
follow
stimul
cell
label
cell
surfac
marker
unconjug
monoclon
antibodi
becton
dickenson
conjug
hous
vivid
stain
invitrogen
fix
permeabil
bd
cytofixcytoperm
becton
dickenson
intracellular
cytokin
stain
becton
dickenson
background
costimul
alon
subtract
determin
antigenspecif
respons
multiscreen
ninetysix
well
plate
coat
overnight
per
well
antihuman
bd
pharmingen
endotoxinfre
dulbeccospb
dpb
plate
wash
three
time
dpb
contain
block
hr
rpmi
contain
fb
remov
incub
peptid
pool
pbmc
triplic
reaction
volum
follow
hr
incub
plate
wash
nine
time
dpb
contain
distil
water
plate
incub
biotinyl
rabbit
antihuman
biosourc
hr
room
temperatur
wash
six
time
dpb
contain
incub
hr
dilut
streptavidinap
southern
biotechnolog
five
wash
dpb
contain
one
dpb
plate
develop
nbtbcip
chromogen
pierc
stop
wash
tap
water
air
dri
read
elispot
reader
use
immunospot
softwar
version
cellular
technolog
ltd
shaker
height
oh
vitro
replic
rmv
encod
siv
gag
similar
parent
ez
vaccin
strain
transgen
express
confirm
western
blot
immunogen
observ
immunocompet
mice
rhesu
macaqu
data
shown
determin
immunogen
rmv
heterolog
primeboost
vaccin
vector
compon
immun
rhesu
macaqu
rmvgag
either
prime
boost
use
highli
immunogen
ae
deliveri
platform
figur
studi
two
dose
compar
either
pfu
approxim
singl
human
dose
twentyfold
greater
pfu
administ
twice
prime
singl
pu
ae
immun
dose
administ
twice
boost
prime
immun
space
week
apart
separ
experi
studi
abil
rmv
prime
system
boost
mucos
im
prime
regimen
subsequ
boost
suboptim
dose
pu
figur
studi
b
two
dose
rmv
use
studi
also
compar
studi
b
anim
receiv
either
rmvgag
rmv
without
insert
rmvnull
assess
immunogen
rmv
vector
alon
vaccin
prime
boost
first
employ
highli
immunogen
aerosol
vaccin
deliveri
system
studi
previous
observ
cell
respons
immunogen
rang
subset
bal
follow
aerosol
vaccin
sinc
five
nine
studi
anim
mv
seroposit
start
presum
due
natur
mv
exposur
anim
divid
prime
group
one
rmv
prime
group
follow
aerosol
rmvgag
immun
anim
mount
signific
serum
igg
respons
rmv
vector
regardless
rmv
dose
figur
note
vaccineinduc
respons
similar
magnitud
igg
level
five
anim
seroposit
studi
start
indic
robust
humor
respons
vaccin
addit
cell
specif
mv
n
protein
also
detect
bal
anim
four
week
homolog
rmv
boost
except
one
mv
seroposit
anim
rang
subset
measur
intracellular
cytokin
stain
follow
ex
vivo
peptid
stimul
ic
figur
signific
differ
group
respect
magnitud
cell
respons
moreov
one
anim
preexist
mv
titer
vigor
nspecif
cell
respons
presum
elicit
vaccin
sinc
mvseroposit
anim
receiv
rmv
prime
group
data
consist
previou
observ
aerosol
vaccin
vector
resist
neutral
preexist
serum
antibodi
vector
lowfrequ
cell
respons
also
observ
half
anim
thu
aerosol
deliveri
rmv
alon
elicit
robust
system
igg
local
mucos
cell
respons
mv
vector
assess
immun
respons
siv
gag
immunogen
measur
serum
igg
blood
bal
cell
respons
signific
gagspecif
igg
observ
time
point
studi
includ
immun
data
shown
surpris
sinc
singl
aerosol
immun
encod
env
hiv
transgen
dose
previous
shown
elicit
serum
igg
respons
may
due
greater
immunogen
env
rel
gag
gagspecif
blood
cell
respons
rmv
prime
boost
also
undetect
figur
data
shown
contrast
induc
demonstr
statist
signific
cell
respons
week
postprim
figur
transient
therefor
consist
boost
rmv
sinc
aerosol
immun
typic
result
except
cell
respons
bal
consid
bal
sensit
site
detect
respons
measur
gagspecif
respons
ic
week
follow
rmv
prime
immun
four
six
anim
prime
rmv
small
notabl
cell
respons
bal
week
first
prime
two
group
figur
respons
rang
cell
subset
declin
second
rmv
immun
one
anim
contrast
prime
elicit
robust
durabl
gagspecif
bal
cell
respons
anim
peak
cell
four
week
immun
evid
rmv
administ
week
boost
respons
howev
without
match
control
exclud
possibl
enhanc
durabl
observ
trend
rmv
prime
greater
magnitud
cell
respons
week
follow
immun
compar
unprim
figur
thu
aerosol
rmv
alon
weak
vector
platform
potenti
enhanc
respons
elicit
subsequ
boost
immun
elabor
abil
rmv
prime
immun
seen
studi
immun
second
group
rhesu
macaqu
rmv
follow
low
dose
ordinarili
would
elicit
robust
respons
studi
b
figur
use
dose
studi
rmv
administ
im
first
assess
rmv
mucos
prime
homolog
system
boost
im
boost
given
week
second
rmv
im
immun
week
serum
igg
elicit
measl
viru
vector
within
two
week
deliveri
studi
b
figur
indic
success
vaccin
take
respons
mv
similar
null
siv
gagencod
rmv
rang
uml
week
two
week
four
appar
effect
dose
titer
increas
slightli
week
eight
peak
two
week
im
rmv
boost
week
titer
suffici
mediat
mv
neutral
figur
contrast
anim
mount
system
igg
respons
gag
insert
follow
rmv
immun
measur
elisa
data
shown
gagspecif
b
cell
like
elicit
rmv
two
anim
one
group
anim
respond
boost
igg
titer
anim
increas
preimmun
level
week
week
week
anim
underw
increas
titer
week
undetect
respons
rmv
alon
mucos
iga
respons
larg
undetect
signific
gagspecif
respons
bronchoalveolar
lavag
bal
saliva
rectum
data
shown
togeth
data
demonstr
robust
immunogen
elicit
rmvgag
measl
viru
vector
weak
humor
respons
siv
gag
insert
consist
ae
deliveri
determin
rmv
prime
cellular
respons
suggest
studi
measur
cell
respons
ic
elispot
follow
rmv
prime
limit
dose
boost
rmv
immun
fail
induc
robust
cell
respons
peripher
blood
time
point
week
signific
differ
preimmun
level
either
vaccin
group
figur
data
shown
lowlevel
respons
observ
anim
within
group
elispot
gener
exceed
antigenspecif
cell
per
million
cell
notabl
two
anim
mount
signific
serum
gag
igg
respons
follow
rmv
also
modest
durabl
cell
respons
data
shown
similarli
gag
elispot
respons
homolog
im
rmv
boost
low
evid
boost
group
week
rel
week
follow
boost
howev
signific
pbmc
cell
respons
detect
rmvgag
prime
group
two
week
four
week
week
boost
respect
versu
week
figur
contrast
cell
respons
dose
undetect
without
prime
mvnull
elispot
pbmc
respons
corrobor
ic
individu
cell
subset
expect
rmvgag
immun
prime
cell
respons
rel
figur
prime
also
trend
toward
signific
elev
cell
respons
half
anim
contrast
pbmc
cell
respons
significantli
prime
rmv
measur
ic
larg
gagspecif
respons
also
measur
bal
follow
boost
anim
prime
rmvgag
particularli
within
cell
compart
figur
combin
data
demonstr
distinct
abil
rmv
prime
cell
respons
studi
assess
immunogen
recombin
live
attenu
edmonston
zagreb
ez
measl
strain
express
sivgag
transgen
rmvgag
prime
vaccin
vector
heterolog
primeboost
regimen
deliv
either
aerosol
combin
intratrach
intramuscular
rout
rmvgag
increas
magnitud
gagspecif
peripher
blood
bal
cell
respons
follow
boost
particularli
among
cell
contrast
humor
respons
transgen
significantli
enhanc
rmv
despit
elicit
strong
function
antibodi
mv
vector
rmv
elicit
robust
measlesspecif
immun
fail
induc
transgenespecif
respons
find
consist
result
initi
test
vector
rhesu
macaqu
rmvgag
administ
intramuscularli
homolog
primeboost
data
shown
rmv
deriv
ez
strain
thu
potent
vaccin
measl
immunogen
vector
transgen
unless
combin
anoth
vector
adenoviru
heterolog
primeboost
regimen
context
rmv
prime
strong
cellular
respons
transgen
even
suboptim
boost
reason
transgen
immunogen
weak
rmv
administ
despit
robust
measlesspecif
respons
probabl
due
limit
replic
attenu
vaccin
strain
replic
measl
viru
singlestrand
negativesens
rna
viru
necessari
highlevel
transgen
protein
synthesi
measl
protein
present
within
vaccin
prime
immun
respons
boost
small
quantiti
measl
protein
produc
upon
lowlevel
viral
replic
highlevel
transgen
protein
avail
immun
respons
elicit
depend
extent
vector
replic
ez
measl
strain
use
gener
rmvgag
vector
highli
attenu
demonstr
superb
safeti
infant
may
thu
explain
poor
immunogen
rmvgag
transgen
use
standalon
vaccin
although
confirm
gag
protein
express
vitro
western
blot
data
shown
possibl
amount
gag
protein
produc
measl
vector
insuffici
elicit
detect
immun
respons
adequ
prime
cell
subsequ
boost
also
exclud
potenti
defect
antigen
process
present
rmvencod
transgen
would
occur
transgen
mv
protein
evid
improv
transgen
express
attenu
measl
viru
vector
achiev
insert
transgen
upstream
n
gene
socal
posit
transcript
express
gradient
n
l
n
express
highest
howev
approach
might
neg
impact
vector
genet
stabil
replic
kinet
altern
strategi
might
develop
transgen
protein
packag
integr
compon
measl
virion
possibl
allow
induct
potent
transgenespecif
humor
respons
tcell
prime
observ
nonhuman
primat
studi
although
effect
pronounc
studi
b
compar
studi
differ
may
due
sever
factor
first
rmv
administ
exclus
airway
mucosa
studi
wherea
one
rmv
prime
studi
b
administ
im
system
rmv
prime
may
enhanc
blood
cellular
respons
greater
extent
ae
deliveri
addit
administ
differ
rout
aerosol
deliveri
studi
less
immunogen
peripher
blood
cell
respons
im
deliveri
studi
b
limit
magnitud
pbmc
respons
studi
furthermor
differ
dose
use
studi
although
clear
suboptim
dose
pu
studi
b
would
induc
larger
respons
optim
dose
pu
studi
prime
dose
rmv
final
interv
rmv
prime
boost
much
greater
studi
b
week
studi
week
may
allow
time
rmvgag
replic
transgen
synthesi
immun
present
although
conclud
time
factor
crucial
observ
differ
fact
observ
tcell
prime
rmv
two
independ
differ
heterolog
primeboost
studi
underscor
robust
mechan
hypothes
prime
abil
rmv
limit
boost
like
live
viral
vector
would
suitabl
boost
vaccin
rmv
heterolog
primeboost
regimen
signific
gagspecif
antibodi
respons
observ
time
point
studi
suggest
weak
prime
cell
bcell
help
compar
cell
howev
gagspecif
antibodi
induc
immun
either
data
shown
lack
gag
antibodi
respons
might
due
rel
poor
immunogen
gag
sinc
previous
demonstr
singl
aerosol
immun
encod
env
hiv
transgen
dose
elicit
serum
igg
respons
anoth
studi
recombin
version
edmonston
b
mv
induc
robust
env
hiv
transgeneand
mvspecif
antibodi
respons
nonhuman
primat
suggest
env
immunogen
gag
howev
exclud
possibl
transgenespecif
respons
due
higher
replic
ie
less
attenu
measl
strain
employ
rel
rmv
main
find
rmv
effici
prime
cell
heterolog
primeboost
regimen
suboptim
boost
dose
adenoviru
vector
import
implic
vaccin
design
gener
heterolog
primeboost
regimen
appeal
potenti
increas
broaden
respons
well
evad
neutral
antibodi
prime
vector
employ
rmv
vaccin
vector
achiev
steril
immun
measl
addit
prime
respons
anoth
pathogen
singl
immun
would
help
reduc
number
immun
given
children
moreov
specif
regimen
test
offer
addit
advantag
dose
spare
boost
vaccin
increas
avail
dosag
decreas
cost
futur
studi
examin
rmv
prime
combin
boost
vaccin
vector
deliveri
via
differ
rout
enhanc
immunogen
particularli
humor
respons
addit
incorpor
possibl
immunogen
transgen
import
assess
full
potenti
rmv
elicit
transgenespecif
immun
respons
evalu
immunogen
mv
seroposit
anim
follow
protect
studi
establish
anim
challeng
model
ultim
prove
suitabl
technolog
justifi
initi
human
clinic
trial
rmv
vector
immun
prime
cellular
respons
adenoviru
vector
heterolog
boost
rmv
prime
highli
effect
suboptim
dose
boost
vector
recombin
mv
retain
robust
measlesspecif
humor
cellular
immunogen
experiment
schema
rmv
immun
regimen
studi
rhesu
macaqu
immun
pfu
dose
group
pfu
dose
group
rmvgag
twice
aerosol
prime
also
aerosol
third
group
receiv
singl
prime
follow
two
boost
immun
rmvgag
aerosol
immun
administ
eight
week
apart
b
studi
b
anim
receiv
either
rmvnull
rmvgag
deliv
twice
intratrach
week
intramuscularli
im
week
half
anim
receiv
dose
half
heterolog
boost
pu
administ
im
anim
week
second
rmv
